• Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. • More detailed trial results will be submitted for presentation at the annual meeting of the American Society of Clinical Oncology. • The post Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% appeared first on MedCity News .

Article Summaries:

  • Grail’s Galleri blood‑screening test failed to achieve statistical significance in a large cancer‑screening study, prompting a 50 % drop in the company’s shares. The company noted a trending improvement in the data and plans to extend patient follow‑up by up to one year to gather additional evidence. Grail will submit more detailed trial results for presentation at the upcoming annual meeting of the American Society of Clinical Oncology. The announcement was first reported by MedCity News.

Sources: